Human Immunodeficiency Virus Clinical Trial
Official title:
Observational Study of HIV-associated Neurocognitive Disorder
It is estimated that over 1 million people in the United States have HIV infection. While HIV
is treatable, there are still high rates of HIV-associated neurocognitive disorder (HAND).
HAND is defined by low scores on memory testing. To meet the criteria for HAND, an
HIV-infected individual has to have a low score on at least two different memory tests. It is
estimated that 20-50% of people living with HIV have HAND. It is therefore still a common
problem. While individuals with HAND typically improve on antiretroviral therapy for HIV,
often this improvement is incomplete. Also, there are over 20 antiretroviral medications
approved for HIV in the US. It is not clear if the specific choice of antiretroviral
medication makes a difference in the improvement of HAND.
The investigators have designed a small preliminary study in which subjects with and without
HAND who have never been on treatment for HIV or have been off treatment for at least 6
months are followed for the first 12 months after starting antiretroviral therapy.The
investigators will enroll a maximum of 46 subjects (23 subjects in each arm). Subjects will
also be followed by their primary HIV medical provider. For the study, subjects will be
followed for 48 weeks. There are three followup visits: 12 weeks, 24 weeks, and 48 weeks.
Memory testing will be performed at baseline and each followup visit. Blood will also be
taken at baseline and the three followup visits to measure changes in inflammation. A lumbar
puncture will be performed at baseline and at 24 weeks to measure changes in inflammation and
amount of HIV virus in the spinal fluid. There is also an optional lumbar puncture at the
last study visit of 48 weeks
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT03516318 -
Using Social Media to Improve ART Retention and Treatment Outcomes Among YLHIV in Nigeria
|
N/A | |
| Completed |
NCT04653194 -
Efficacy of BIC/F/TAF Versus Standard of Care in the Treatment of New HIV Infection Diagnoses in the Context of 'Test and Treat'
|
Phase 3 | |
| Completed |
NCT01792570 -
DRV/r + RPV QD: Efficacy and Toxicity Reduction
|
Phase 3 | |
| Active, not recruiting |
NCT04826562 -
Switch to DOVATO in Patients Suppressed on Biktarvy (SOUND)
|
Phase 4 | |
| Completed |
NCT04191967 -
Thermocoagulation for Treatment of Precancerous Cervical Lesions
|
N/A | |
| Completed |
NCT02812329 -
Intervention to Encourage HIV Testing and Counseling Among Adolescents
|
Phase 1 | |
| Completed |
NCT02919306 -
Safety and Efficacy Study of Vaccine Schedule With Ad26.Mos.HIV and MVA-Mosaic in Human Immunodeficiency Virus (HIV)-Infected Adults
|
Phase 1/Phase 2 | |
| Completed |
NCT02651376 -
Safety and Efficacy of Allogenic Adoptive Immune Therapy for Advanced AIDS Patients
|
Phase 1/Phase 2 | |
| Completed |
NCT02516930 -
A Non-inferiority Randomized Controlled Trial to Evaluate Promoting Condom Use Among MSM and Transgender Individuals in China
|
N/A | |
| Recruiting |
NCT02392884 -
HIV Medication Adherence in Underserved Populations
|
N/A | |
| Completed |
NCT01944371 -
Short-term Disulfiram Administration to Reverse Latent HIV Infection: a Dose Escalation Study
|
Phase 1/Phase 2 | |
| Recruiting |
NCT01778374 -
Mater-Bronx Rapid HIV Testing Project.
|
N/A | |
| Completed |
NCT00914225 -
Effect of Bednets and a Water Purification Device on HIV Disease Progression Among ART naïve Patients in Kenya
|
N/A | |
| Completed |
NCT01490346 -
Tissue Drug Levels of HIV Medications
|
N/A | |
| Completed |
NCT01460433 -
Problems With Immune Recovery in the Gut Tissue
|
N/A | |
| Completed |
NCT01076179 -
Kaletra in Combination With Antiretroviral Agents
|
N/A | |
| Completed |
NCT00317460 -
Buprenorphine and Integrated HIV Care
|
Phase 4 | |
| Terminated |
NCT04240210 -
Integrase Regimen Switch to Symtuza to Increase Tolerability/Adherence (SYMita)
|
Phase 4 | |
| Active, not recruiting |
NCT04704336 -
Integration of Hypertension Management Into HIV Care in Nigeria
|
N/A | |
| Completed |
NCT03254277 -
3BNC117-LS First-in-Human Phase 1 Study
|
Phase 1 |